Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 – 2017)
Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period.
KEY DRIVER:
Advances in cell research and therapeutic delivery
Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.
KEY RESTRAINT:
Home brewReagents restricts sale of commercial kits
Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.
KEY CHALLENGE:
New disruptive technologies required to address transfection in hard-to-transfect cells
Transfection is an enabler technology which is used in many cell research activities, however only few cell lines are majorly used in these experiments restricting the scope of the study. Transfection in hard to transfect cells is the need of hour and it is a major challenge. There are few upcoming transfection technologies like nucleofection and magnetofection – which are an off-shoot of electroporation, which have the potential to address these challenges but are currently cost prohibitive due to which the technologies may have a much slower uptake in the developing world.
The report also discusses new opportunities for investment in the upcoming areas like Gene therapy, Stem cell research and Electro-chemotherapy.
Different transfection technologies are analyzed through a multi-criteria based decision making process which provides competitive benchmarking. Further, the report analyses technology management strategies and technology road mapping for the forecast period. Profiles of over 20 Key companies in the area of Transfection technology sector have been provided. Key players include Life Technologies, Sigma Aldrich, Lonza, Promega, Qiagen, Bio-Rad, Roche, Polyplus Transfection, Mirius Bio, Maxcyte, etc.
SCOPE OF THE REPORT
A comprehensive analysis of the market size and global revenue has been forecasted based on four segmentation: technology, products, applications and by geography.
On the Basis of Applications: Transfection market is segmented into three categories 1. Therapeutic delivery, 2. Bio-Medical research, 3. Protein production. A brief description of the applications and their revenue is discussed in detail in the report.
On the Basis of Product Type: They have been segmented into two types namely, Reagent and Instrument based.
On the Basis of Geography: North America, Europe, Asia-Pacific, and ROW.
On the Basis of Technology: They have been classified into three categories 1. Physical based transfection, 2. Biochemical based Transfection 3. Viral based transfection. Revenue and forecasts for the growth of these technologies has been discussed in detail.
KEY DRIVER:
Advances in cell research and therapeutic delivery
Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.
KEY RESTRAINT:
Home brewReagents restricts sale of commercial kits
Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.
KEY CHALLENGE:
New disruptive technologies required to address transfection in hard-to-transfect cells
Transfection is an enabler technology which is used in many cell research activities, however only few cell lines are majorly used in these experiments restricting the scope of the study. Transfection in hard to transfect cells is the need of hour and it is a major challenge. There are few upcoming transfection technologies like nucleofection and magnetofection – which are an off-shoot of electroporation, which have the potential to address these challenges but are currently cost prohibitive due to which the technologies may have a much slower uptake in the developing world.
The report also discusses new opportunities for investment in the upcoming areas like Gene therapy, Stem cell research and Electro-chemotherapy.
Different transfection technologies are analyzed through a multi-criteria based decision making process which provides competitive benchmarking. Further, the report analyses technology management strategies and technology road mapping for the forecast period. Profiles of over 20 Key companies in the area of Transfection technology sector have been provided. Key players include Life Technologies, Sigma Aldrich, Lonza, Promega, Qiagen, Bio-Rad, Roche, Polyplus Transfection, Mirius Bio, Maxcyte, etc.
SCOPE OF THE REPORT
A comprehensive analysis of the market size and global revenue has been forecasted based on four segmentation: technology, products, applications and by geography.
On the Basis of Applications: Transfection market is segmented into three categories 1. Therapeutic delivery, 2. Bio-Medical research, 3. Protein production. A brief description of the applications and their revenue is discussed in detail in the report.
On the Basis of Product Type: They have been segmented into two types namely, Reagent and Instrument based.
On the Basis of Geography: North America, Europe, Asia-Pacific, and ROW.
On the Basis of Technology: They have been classified into three categories 1. Physical based transfection, 2. Biochemical based Transfection 3. Viral based transfection. Revenue and forecasts for the growth of these technologies has been discussed in detail.
1. INTRODUCTION
1.1 Key Take-Aways
1.2 Report Scope
1.3 Research Methodology
1.4 Key Data Points From Secondary Sources
1.5 Key Data Points From Primary Sources
2. EXECUTIVE SUMMARY
3. TRANSFECTION TECHNOLOGIES – TECHNOLOGY LANDSCAPE ANALYSIS
3.1 Technology Overview (Introduction, Evolution and Market Segmentation)
3.2 Technology Value Chain Analysis (with Technology Capability/Maturity Levels)
3.3 Comparative Analysis Of Transfection Methods (Physical, biochemical and Viral)
3.4 Applications
3.4.1 Therapeutic delivery
3.4.1.1 Bio-Therpeutics (gene delivery, protein delivery)
3.4.1.2 ElectroChemotherapy and Electro-immunotherapy
3.4.2 Bio-Medical research
3.4.2.1 Transgenic models
3.4.2.2 Gene and protein expression studies
3.4.2.3 Cancer research
3.4.2.4 Cell based microarrays for drug discovery and development
3.4.3 Protein production (Recombinant protein, Vaccines)
4. TRANSFECTION - MARKET LANDSCAPE ANALYSIS
4.1 Global Market Forecast
4.1.1 By Geography
4.1.2 By Products
4.1.3 By Application
4.1.4 By Technology
4.2 Market Dynamics
4.2.1 Drivers (with timeline)
4.2.2 Restraints/Challenges (with timeline)
4.2.3 Emerging Trends
5. GLOBAL R&D PORTFOLIO ANALYSIS
5.1 Key R&D Networks – Current & Emerging – This segment will include university – Incubator divisions; company – VC funded corporate incubator divisions)
5.2 Universities With Potential Technologies For Licensing/Tech Transfer; Form Spin Offs
6. INVESTMENT/FUNDING ANALYSIS
6.1 Investment Climate Assessment
6.2 Investments On Transfection
7. TRANSFECTION – DIFFUSION ANALYSIS
7.1 Technology adoption and development-Geographical analysis
7.1.1 Introduction
7.1.2 North America
7.1.3 Europe
7.1.3.1 Key research areas based on Electroporation in European Union
7.1.3.2 Funding and development activities in European union
7.1.4 APAC
7.1.5 ROW
8. COMPETITIVE LANDSCAPE
8.1 Mergers & Acquisitions, 2007 – 2012
8.2 Partnerships & Collaborations, 2007 – 2012
8.3 New Product/Technology Development Initiatives
8.4 Market Share Analysis of Key Players - 2012
9. OPPORTUNITY EVALUATION AND TECHNOLOGY BENCHMARKING/ROADMAPPING
9.1 Scenario Modeling
9.2 Evaluation Of Emerging Opportunities
9.3 Technology Benchmarking Based On Multicriteria Decision Making
9.4 Technology Road mapping
10. PATENT ANALYSIS
11. ANALYST INSIGHTS AND RECOMMENDATIONS
11.1 Introduction
11.2 Technology Management Strategies
12. COMPANY PROFILES
12.1 LIFE TECHNOLOGIES CORPORATION
12.2 LONZA GROUP LTD.
12.3 PROMEGA CORPORATION
12.4 SIGMA ALDRICH CORPORATION
12.5 THERMO FISHER SCIENTIFIC INC.
12.6 BIO-RAD LABORATORIES INC.
12.7 ROCHE APPLIED SCIENCE
12.8 QIAGEN N.V., 12.9 INOVIO PHARMACEUTICALS INC., 12.10 POLYPLUS TRANSFECTION S.A.
12.11 MIRUS BIO LLC.
12.12 CLONETECH LABORATORIES, INC.
12.13 SIGNAGEN LABORATORIES
12.14 MAXCYTE, INC.
12.15 NANOTHERICS
12.16 GENLANTIS
12.17 TECHULON INC., 12.18 DELIVERICS LTD.
12.19 OZ BIOSCIENCES
12.20 MOLECULAR TRANSFER INC., 12.21 ALTOGEN BIOSYSTEMS
12.22 PROMOKINE GMBH
13. APPENDIX
14. GLOSSARY
1.1 Key Take-Aways
1.2 Report Scope
1.3 Research Methodology
1.4 Key Data Points From Secondary Sources
1.5 Key Data Points From Primary Sources
2. EXECUTIVE SUMMARY
3. TRANSFECTION TECHNOLOGIES – TECHNOLOGY LANDSCAPE ANALYSIS
3.1 Technology Overview (Introduction, Evolution and Market Segmentation)
3.2 Technology Value Chain Analysis (with Technology Capability/Maturity Levels)
3.3 Comparative Analysis Of Transfection Methods (Physical, biochemical and Viral)
3.4 Applications
3.4.1 Therapeutic delivery
3.4.1.1 Bio-Therpeutics (gene delivery, protein delivery)
3.4.1.2 ElectroChemotherapy and Electro-immunotherapy
3.4.2 Bio-Medical research
3.4.2.1 Transgenic models
3.4.2.2 Gene and protein expression studies
3.4.2.3 Cancer research
3.4.2.4 Cell based microarrays for drug discovery and development
3.4.3 Protein production (Recombinant protein, Vaccines)
4. TRANSFECTION - MARKET LANDSCAPE ANALYSIS
4.1 Global Market Forecast
4.1.1 By Geography
4.1.2 By Products
4.1.3 By Application
4.1.4 By Technology
4.2 Market Dynamics
4.2.1 Drivers (with timeline)
4.2.2 Restraints/Challenges (with timeline)
4.2.3 Emerging Trends
5. GLOBAL R&D PORTFOLIO ANALYSIS
5.1 Key R&D Networks – Current & Emerging – This segment will include university – Incubator divisions; company – VC funded corporate incubator divisions)
5.2 Universities With Potential Technologies For Licensing/Tech Transfer; Form Spin Offs
6. INVESTMENT/FUNDING ANALYSIS
6.1 Investment Climate Assessment
6.2 Investments On Transfection
7. TRANSFECTION – DIFFUSION ANALYSIS
7.1 Technology adoption and development-Geographical analysis
7.1.1 Introduction
7.1.2 North America
7.1.3 Europe
7.1.3.1 Key research areas based on Electroporation in European Union
7.1.3.2 Funding and development activities in European union
7.1.4 APAC
7.1.5 ROW
8. COMPETITIVE LANDSCAPE
8.1 Mergers & Acquisitions, 2007 – 2012
8.2 Partnerships & Collaborations, 2007 – 2012
8.3 New Product/Technology Development Initiatives
8.4 Market Share Analysis of Key Players - 2012
9. OPPORTUNITY EVALUATION AND TECHNOLOGY BENCHMARKING/ROADMAPPING
9.1 Scenario Modeling
9.2 Evaluation Of Emerging Opportunities
9.3 Technology Benchmarking Based On Multicriteria Decision Making
9.4 Technology Road mapping
10. PATENT ANALYSIS
11. ANALYST INSIGHTS AND RECOMMENDATIONS
11.1 Introduction
11.2 Technology Management Strategies
12. COMPANY PROFILES
12.1 LIFE TECHNOLOGIES CORPORATION
12.2 LONZA GROUP LTD.
12.3 PROMEGA CORPORATION
12.4 SIGMA ALDRICH CORPORATION
12.5 THERMO FISHER SCIENTIFIC INC.
12.6 BIO-RAD LABORATORIES INC.
12.7 ROCHE APPLIED SCIENCE
12.8 QIAGEN N.V., 12.9 INOVIO PHARMACEUTICALS INC., 12.10 POLYPLUS TRANSFECTION S.A.
12.11 MIRUS BIO LLC.
12.12 CLONETECH LABORATORIES, INC.
12.13 SIGNAGEN LABORATORIES
12.14 MAXCYTE, INC.
12.15 NANOTHERICS
12.16 GENLANTIS
12.17 TECHULON INC., 12.18 DELIVERICS LTD.
12.19 OZ BIOSCIENCES
12.20 MOLECULAR TRANSFER INC., 12.21 ALTOGEN BIOSYSTEMS
12.22 PROMOKINE GMBH
13. APPENDIX
14. GLOSSARY
LIST OF TABLES
TABLE 1 MAPPING OF TECHNOLOGY CAPABILITY AND MATURITY
TABLE 2 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
TABLE 3 GLOBAL TRANSFECTION MARKET BY GEOGRAPHY, 2012-2017 ($ MILLION)
TABLE 4 GLOBAL TRANSFECTION MARKET REVENUE BY PRODUCTS, 2012-2017 ($ MILLION)
TABLE 5 GLOBAL TRANSFECTION MARKET REVENUE BY APPLICATIONS 2012-2017 ($ MILLION)
TABLE 6 GLOBAL TRANSFECTION MARKET REVENUE BY TECHNOLGY 2012-2017 ($ MILLION)
TABLE 7 MARKET DYNAMICS - DRIVERS IMPACT TIME LINE
TABLE 8 MARKET DYNAMICS - RESTRAINTS IMPACT TIMELINE
TABLE 9 OPPORTUNITY STRATEGIC EVALUATION ANALYSIS
TABLE 1 MAPPING OF TECHNOLOGY CAPABILITY AND MATURITY
TABLE 2 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
TABLE 3 GLOBAL TRANSFECTION MARKET BY GEOGRAPHY, 2012-2017 ($ MILLION)
TABLE 4 GLOBAL TRANSFECTION MARKET REVENUE BY PRODUCTS, 2012-2017 ($ MILLION)
TABLE 5 GLOBAL TRANSFECTION MARKET REVENUE BY APPLICATIONS 2012-2017 ($ MILLION)
TABLE 6 GLOBAL TRANSFECTION MARKET REVENUE BY TECHNOLGY 2012-2017 ($ MILLION)
TABLE 7 MARKET DYNAMICS - DRIVERS IMPACT TIME LINE
TABLE 8 MARKET DYNAMICS - RESTRAINTS IMPACT TIMELINE
TABLE 9 OPPORTUNITY STRATEGIC EVALUATION ANALYSIS
LIST OF FIGURES
FIGURE 1 RESEARCH METHODOLOGY
FIGURE 2 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
FIGURE 3 TECHNOLOGY OVERVIEW
FIGURE 4 TECHNOLOGY VALUE CHAIN ANALYSIS
FIGURE 5 TECHNOLOGY CAPABILITY AND MATURITY
FIGURE 6 TECHNOLOGY LIFE CYCLE ANALYSIS
FIGURE 7 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
FIGURE 8 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY GEOGRAPHY 2012 – 2017
FIGURE 9 GLOBAL TRANSFECTION MARKET SHARE BY GEOGRAPHY 2012
FIGURE 10 GLOBAL TRANSFECTION MARKET REVENUE BY GEOGRAPHY, 2012-2017 ($ MILLION)
FIGURE 11 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY PRODUCTS 2012 – 2017
FIGURE 12 GLOBAL TRANSFECTION MARKET SHARE BY PRODUCTS 2012
FIGURE 13 GLOBAL TRANSFECTION MARKET REVENUE BY PRODUCTS, 2012-2017 ($ MILLION)
FIGURE 14 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY APPLICATIONS 2012 – 2017
FIGURE 15 GLOBAL TRANSFECTION MARKET SHARE BY APPLICATIONS 2012
FIGURE 16 GLOBAL TRANSFECTION MARKET REVENUE BY APPLICATIONS, 2012-2017($ MILLION)
FIGURE 17 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY TECHNOLOGY 2012 – 2017
FIGURE 18 GLOBAL TRANSFECTION MARKET SHARE BY TECHNOLOGY 2012
FIGURE 19 GLOBAL TRANSFECTION MARKET REVENUE BY TECHNOLOGY 2012-2017 ($ MILLION)
FIGURE 20 GLOBAL RESEARCH PORTFOLIO-RESEARCH AND DEVELOPMENT NETWORK
FIGURE 21 ATTRACTIVE FORCES FOR INCREASED MARKET VALUE
FIGURE 22 ADOPTION RATE OF ELECTROCHEMOTHERAPY (2006-2010)
FIGURE 23 FUNDING LANDSCAPE IN EU
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS – 2012
FIGURE 25 OPPORTUNITY STRATEGIC EVALUATION ANALYSIS
FIGURE 26 PRIORITIZATION OF TRANSFECTION TECHNOLOGIES FOR FUTURE ADOPTION
FIGURE 27 PRIORITY VALUES FOR LEVEL
FIGURE 28 COMPARISON OF TECHNOLOGY BASED ON LEVEL 0 CRITERIA
FIGURE 29 TECHNOLOGY PRIORITIZATION
FIGURE 30 NO OF PATENTS PUBLISHED BETWEEN THE YEAR 2007-2012
FIGURE 31 PERCENTAGE DISTRIBUTION: REAGENTS VS PHYSICAL (2007-2012)
FIGURE 1 RESEARCH METHODOLOGY
FIGURE 2 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
FIGURE 3 TECHNOLOGY OVERVIEW
FIGURE 4 TECHNOLOGY VALUE CHAIN ANALYSIS
FIGURE 5 TECHNOLOGY CAPABILITY AND MATURITY
FIGURE 6 TECHNOLOGY LIFE CYCLE ANALYSIS
FIGURE 7 GLOBAL TRANSFECTION MARKET REVENUE, 2012-2017 ($ MILLION)
FIGURE 8 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY GEOGRAPHY 2012 – 2017
FIGURE 9 GLOBAL TRANSFECTION MARKET SHARE BY GEOGRAPHY 2012
FIGURE 10 GLOBAL TRANSFECTION MARKET REVENUE BY GEOGRAPHY, 2012-2017 ($ MILLION)
FIGURE 11 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY PRODUCTS 2012 – 2017
FIGURE 12 GLOBAL TRANSFECTION MARKET SHARE BY PRODUCTS 2012
FIGURE 13 GLOBAL TRANSFECTION MARKET REVENUE BY PRODUCTS, 2012-2017 ($ MILLION)
FIGURE 14 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY APPLICATIONS 2012 – 2017
FIGURE 15 GLOBAL TRANSFECTION MARKET SHARE BY APPLICATIONS 2012
FIGURE 16 GLOBAL TRANSFECTION MARKET REVENUE BY APPLICATIONS, 2012-2017($ MILLION)
FIGURE 17 GLOBAL TRANSFECTION MARKET - GROWTH RATE BY TECHNOLOGY 2012 – 2017
FIGURE 18 GLOBAL TRANSFECTION MARKET SHARE BY TECHNOLOGY 2012
FIGURE 19 GLOBAL TRANSFECTION MARKET REVENUE BY TECHNOLOGY 2012-2017 ($ MILLION)
FIGURE 20 GLOBAL RESEARCH PORTFOLIO-RESEARCH AND DEVELOPMENT NETWORK
FIGURE 21 ATTRACTIVE FORCES FOR INCREASED MARKET VALUE
FIGURE 22 ADOPTION RATE OF ELECTROCHEMOTHERAPY (2006-2010)
FIGURE 23 FUNDING LANDSCAPE IN EU
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS – 2012
FIGURE 25 OPPORTUNITY STRATEGIC EVALUATION ANALYSIS
FIGURE 26 PRIORITIZATION OF TRANSFECTION TECHNOLOGIES FOR FUTURE ADOPTION
FIGURE 27 PRIORITY VALUES FOR LEVEL
FIGURE 28 COMPARISON OF TECHNOLOGY BASED ON LEVEL 0 CRITERIA
FIGURE 29 TECHNOLOGY PRIORITIZATION
FIGURE 30 NO OF PATENTS PUBLISHED BETWEEN THE YEAR 2007-2012
FIGURE 31 PERCENTAGE DISTRIBUTION: REAGENTS VS PHYSICAL (2007-2012)
